The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy

(1) Background: The use of antiangiogenic TKIs (AA-TKIs) has recently emerged as a major paradigm shift in the treatment of advanced sarcoma. However, the feasibility of drug holidays for patients demonstrating a very favorable response remains unknown. (2) Methods: We aim to explore the outcomes of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhusheng, Bao, Qiyuan, Fu, Yucheng, Wen, Junxiang, Li, Meng, Liu, Zhuochao, He, Guoyu, Wang, Beichen, Shen, Yuhui, Zhang, Weibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821264/
https://www.ncbi.nlm.nih.gov/pubmed/36615127
http://dx.doi.org/10.3390/jcm12010325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821264/
https://www.ncbi.nlm.nih.gov/pubmed/36615127
http://dx.doi.org/10.3390/jcm12010325

Ejemplares similares